Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Musculoskeletal
Study Phase : Discovery
Sponsor : SOLVE FSHD
Deal Size : $3.0 million
Deal Type : Financing
SOLVE FSHD Invests US$3 Million in Altay Therapeutics
Details : The investment will support Altay Therapeutics’ unique approach to finding an inhibitor of DUX4, a key transcription factor implicated in FSHD, that could provide an effective disease-modifying treatment.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 21, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Musculoskeletal
Highest Development Status : Discovery
Sponsor : SOLVE FSHD
Deal Size : $3.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?